Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Disparities in ALL treatment toxicity

Taylor OA et al. Clin Cancer Res. 2018 Sep 11. doi: 10.1158/1078-0432.CCR-18-0939

Key clinical point: Hispanic patients with acute lymphoblastic leukemia had a higher risk of methotrexate toxicity compared with non-Hispanic whites.

Major finding: After researchers accounted for age, sex, ALL risk stratification, and other factors, the adjusted hazard ratio was 2.43 (95% CI, 1.06-5.58).

Study details: A prospective multicenter study of 280 patients with newly diagnosed ALL, nearly half of whom were Hispanic.

Disclosures: The research was supported by the National Institutes of Health and Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium, a St. Baldrick’s Foundation Consortium Research Grant. The study authors reported having no potential conflicts of interest.

Read the article here.


Taylor OA et al. Clin Cancer Res. 2018 Sep 11. doi: 10.1158/1078-0432.CCR-18-0939.